Neurodegenerative Disease Market Size, Share & Trends Analysis Report By Drug Class (NMDA, SSRIs, Decarboxylase inhibitors, Cholinesterase Inhibitors, Immunomodulators, Dopamine Inhibitors), By Applications, Region And Segment Forecasts, 2025-2034.

Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions Chapter 2. Executive Summary Chapter 3. Global Neurodegenerative Disease Market Snapshot Chapter 4. Global Neurodegenerative Disease Market Variables, Trends & Scope 4.1. Market Segmentation & Scope 4.2. Drivers 4.3. Challenges 4.4. Trends 4.5. Investment and Funding Analysis 4.6. Industry Analysis – Porter's Five Forces Analysis 4.7. Impact of Covid-19 Analysis Chapter 5. Market Segmentation 1: By Drug Class Estimates & Trend Analysis 5.1. By Drug Class & Market Share, 2024 & 2034 5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Drug Class: 5.2.1. NMDA 5.2.2. SSRIs 5.2.3. Decarboxylase inhibitors 5.2.4. Cholinesterase Inhibitors 5.2.5. Immunomodulators 5.2.6. Dopamine Inhibitors Chapter 6. Market Segmentation 2: By Application Estimates & Trend Analysis 6.1. By Application & Market Share, 2024 & 2034 6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application: 6.2.1. Parkinson's Disease 6.2.2. Huntington Disease 6.2.3. Amyotrophic Lateral Sclerosis 6.2.4. Alzheimer's Disease Chapter 7. Neurodegenerative Disease Market Segmentation 3: Regional Estimates & Trend Analysis 7.1. North America 7.1.1. North America Neurodegenerative Disease Market revenue (US$ Million) estimates and forecasts By Drug Class, 2021 - 2034 7.1.2. North America Neurodegenerative Disease Market revenue (US$ Million) estimates and forecasts By Application, 2021 - 2034 7.1.3. North America Neurodegenerative Disease Market revenue (US$ Million) estimates and forecasts by country, 2021 - 2034 7.2. Europe 7.2.1. Europe Neurodegenerative Disease Market revenue (US$ Million) By Drug Class, 2021 - 2034 7.2.2. Europe Neurodegenerative Disease Market revenue (US$ Million) By Application, 2021 - 2034 7.2.3. Europe Neurodegenerative Disease Market revenue (US$ Million) by country, 2021 - 2034 7.3. Asia Pacific 7.3.1. Asia Pacific Neurodegenerative Disease Market revenue (US$ Million) By Drug Class, 2021 - 2034 7.3.2. Asia Pacific Neurodegenerative Disease Market revenue (US$ Million) By Application, 2021 - 2034 7.3.3. Asia Pacific Neurodegenerative Disease Market revenue (US$ Million) by country, 2021 - 2034 7.4. Latin America 7.4.1. Latin America Neurodegenerative Disease Market revenue (US$ Million) By Drug Class, (US$ Million) 7.4.2. Latin America Neurodegenerative Disease Market revenue (US$ Million) By Application, (US$ Million) 7.4.3. Latin America Neurodegenerative Disease Market revenue (US$ Million) by country, (US$ Million) 2021 - 2034 7.5. Middle East & Africa 7.5.1. Middle East & Africa Neurodegenerative Disease Market revenue (US$ Million) By Drug Class, (US$ Million) 7.5.2. Middle East & Africa Neurodegenerative Disease Market revenue (US$ Million) By Application, (US$ Million) 7.5.3. Middle East & Africa Neurodegenerative Disease Market revenue (US$ Million) by country, (US$ Million) 2021 - 2034 Chapter 8. Competitive Landscape 8.1. Major Mergers and Acquisitions/Strategic Alliances 8.2. Company Profiles 8.2.1. Novartis 8.2.2. Pfizer 8.2.3. Merck Serono 8.2.4. Biogen Idec 8.2.5. TEVA 8.2.6. UCB 8.2.7. Boehringer Ingelheim 8.2.8. Sanofi 8.2.9. GlaxoSmithKline 8.2.10. Other Key Players